IDV vehicle
36E79723D0022
NEW AWARD FOR RENFLEXIS (INFLIXIMAB-ABDA) 100MG VIAL WITH ORGANON LLC. ORDERING PERIOD IS SEPTEMBER 1, 2023 TO AUGUST 31, 2024 WITH FOUR ONE-YEAR OPTIONS.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Veterans Affairs |
| Office | NAC PHARMACEUTICALS (36E797) |
| NAICS | 325412 — Pharmaceutical Preparation Manufacturing |
| PSC | 6505 — Drugs and Biologicals |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $0 |
| Current contract value | Not reported |
| Potential contract value / ceiling | $119.5M |
| Start date | Sep 1, 2023 |
| Current end date | Not available |
| Potential end date | Not available |
| Latest award activity | Sep 1, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 15 of 15 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 1, 2026 | P00014 | $0 | MODIFICATION TO INCORPORATE SECTION 5 OF EO 14398, CLAUSE 52.222-90, ADDRESSING DEI DISCRIMINATION BY FEDERAL CONTRACTORS (APR 2026), INTO THE CONTRACT. |
| Jun 24, 2026 | P00013 | $0 | EXERCISE OPTION YEAR 3, EFFECTIVE SEPTEMBER 1, 2026 - AUGUST 31, 2027, FOR INFLIXIMAB-ABDA (RENFLEXIS) WITH ORGANON LLC. |
| Jan 5, 2026 | P00012 | $0 | INCORPORATION OF 2026 SMALL BUSINESS SUBCONTRACTING PLAN INTO CONTRACT 36E79723D0022 - RENFLEXIS (INFLIXIMAB-ABDA). |
| Dec 2, 2025 | P00011 | $0 | INCORPORATION OF 2026 FEDERAL CEILING PRICE INTO CONTRACT. THE AWARDED NATIONAL CONTRACT PRICE REMAINS UNCHANGED. |
| Jul 8, 2025 | P00010 | $0 | EXERCISE OPTION YEAR 2, EFFECTIVE SEPTEMBER 1, 2025 - AUGUST 31, 2026 FOR RENFLEXIS (INFLIXIMAB ABDA) WITH ORGANON LLC. |
| Jan 28, 2025 | P00009 | $0 | CONTRACTOR ADMINISTRATIVE POC CHANGE FOR DESIGNATED NEGOTIATOR ON CONTRACT 36E79723D0022 - RENFLEXIS (INFLIXIMAB-ABDA). |
| Jan 22, 2025 | P00008 | $0 | INCORPORATION OF 2025 SMALL BUSINESS SUBCONTRACTING PLAN INTO CONTRACT 36E79723D0022 - RENFLEXIS (INFLIXIMAB-ABDA). |
| Nov 21, 2024 | P00007 | $0 | INCORPORATION OF 2025 FEDERAL CEILING PRICE INTO CONTRACT. THE AWARDED NATIONAL CONTRACT PRICE REMAINS UNCHANGED. |
| Jun 25, 2024 | P00006 | $0 | EXERCISE OPTION YEAR 1, EFFECTIVE SEPTEMBER 1, 2024 - AUGUST 31, 2025 FOR RENFLEXIS (INFLIXIMAB ABDA) WITH ORGANON LLC. |
| Feb 21, 2024 | P00004 | $0 | MODIFICATION FOR THE SUPPLEMENTAL CHANGES TO THE CRF PAYMENT SUBMITTAL AND SALES REPORTING REQUIREMENTS. |
| Feb 20, 2024 | P00005 | $0 | CONTRACTOR ADMINISTRATIVE AND SALES POC CHANGE ON CONTRACT. |
| Dec 18, 2023 | P00003 | $0 | INCORPORATION OF 2024 SMALL BUSINESS SUBCONTRACTING PLAN INTO CONTRACT 36E79723D0022 - RENFLEXIS (INFLIXIMAB-ABDA). |
| Dec 6, 2023 | P00002 | $0 | INCORPORATION OF 2024 FEDERAL CEILING PRICE INTO CONTRACT. THE AWARDED NATIONAL CONTRACT PRICE REMAINS UNCHANGED. |
| May 8, 2023 | P00001 | $0 | THIS MODIFICATION IS ISSUED TO INCORPORATE THE DRUG SUPPLY CHAIN SECURITY ACT (DSCSA) LANGUAGE INTO THE CONTRACT. |
| May 3, 2023 | 0 | $0 | NEW AWARD FOR RENFLEXIS (INFLIXIMAB-ABDA) 100MG VIAL WITH ORGANON LLC. ORDERING PERIOD IS SEPTEMBER 1, 2023 TO AUGUST 31, 2024 WITH FOUR ONE-YEAR OPTIONS. |
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.